PRNewswire

Top Fire watch organizations throughout the state of California

SAN JOSE, Calif., June 2, 2024 /PRNewswire/ -- Fast Guard Service, a leading provider of security guard services, has released "The Ultimate Guide to Choosing the Best Fire Watch Service." This guide aims to assist business owners and property managers in making informed decisions when hiring fire watch security guards.

Why Fire Watch Services Are Essential

Ensuring safety and compliance is critical for... (continue reading...)

• The global pivotal WU-KONG1B study investigating sunvozertinib achieved its primary objective with a manageable safety profile in relapsed or refractory NSCLC with EGFR exon20ins.
• An ongoing randomized global Phase III study (WU-KONG28) is assessing sunvozertinib versus platinum containing doublets in NSCLC with EGFR exon20ins in the first-line setting.

SHANGHAI, June 2, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel... (continue reading...)

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1... (continue reading...)

SUZHOU, China, and ROCKVILLE, Md., June 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of its novel drug candidate AGP-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor (TKI), in patients with non-small-cell lung cancer (NSCLC) in a poster presentation at the 60th American Society... (continue reading...)

BEIJING and SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) in frontline non-small cell lung cancer (NSCLC) patients harboring KRAS G12C mutation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting as form of oral presentation. Jacobio... (continue reading...)